Compare Deckers Outdoor Corp (DECK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs TG Therapeutics Inc — how do they compare? Deckers Outdoor Corp trades at $93.39 (market cap $12.78B), while TG Therapeutics Inc trades at $50.29 (market cap $7.64B). The key difference: Deckers Outdoor Corp is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| DECK | TGTX | |
|---|---|---|
Market Cap | $12.78B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $123.91 | $59.06 |
52-Week Low | $79.54 | $26.94 |
Enterprise Value | $11.65B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $93.75, down 3.79% over 24 hours, with technical indicators signaling a bearish trend. Fundamentally, the company shows strength with a trailing P/E of 13.35, robust net income margin of 18.36%, and consistent earnings beats in recent quarters. Revenue grew to $4.99B in 2025, and cash flow from operations remains strong at $1.04B. Recent news highlights mixed sentiment amid sector-wide pressures, particularly following weaker guidance from peer On Holding.
The outlook for DECK is cautiously optimistic, supported by solid fundamentals and a consensus price target of $122.40, implying significant upside. However, risks include competitive pressures in the footwear sector, potential tariff impacts, and recent bearish technical signals. The stock's current valuation presents a potential opportunity if execution remains strong, but investors should weigh near-term volatility against long-term growth prospects.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
